PTC Therapeutics, Inc. Cost of Revenue
PTC Therapeutics, Inc. (PTCT) reported Cost of Revenue of $12.13 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-02.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfGoodsAndServicesSold · last filed 2020-03-02
- PTC Therapeutics, Inc. cost of goods and services sold for the quarter ending 2019-12-31 was $3.54M, a 5.82% decline year-over-year.
- PTC Therapeutics, Inc. cost of goods and services sold for the quarter ending 2019-09-30 was $3.01M, a 8.69% decline year-over-year.
- PTC Therapeutics, Inc. cost of goods and services sold for the quarter ending 2019-06-30 was $3.21M, a 24.84% increase year-over-year.
- PTC Therapeutics, Inc. cost of goods and services sold for the quarter ending 2019-03-31 was $2.38M, a 21.97% decline year-over-year.
- PTC Therapeutics, Inc. cost of goods and services sold for fiscal 2019 was $12.13M, a 4.22% decline from fiscal 2018.
- PTC Therapeutics, Inc. cost of goods and services sold for fiscal 2018 was $12.67M, a 176.82% increase from fiscal 2017.
- PTC Therapeutics, Inc. cost of goods and services sold for fiscal 2017 was $4.58M.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2019-12-31 | $3.54M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $6.55M derived: sum of 2 quarters · filed 2020-03-02 | $9.76M derived: sum of 3 quarters · filed 2020-03-02 | $12.13M 10-K · filed 2020-03-02 |
| 2019-09-30 | $3.01M 10-Q · filed 2019-10-30 | $6.22M derived: sum of 2 quarters · filed 2019-10-30 | $8.59M 10-Q · filed 2019-10-30 | $12.35M derived: sum of 4 quarters · filed 2020-03-02 |
| 2019-06-30 | $3.21M 10-Q · filed 2019-08-06 | $5.59M 10-Q · filed 2019-08-06 | $9.35M derived: sum of 3 quarters · filed 2020-03-02 | $12.64M derived: sum of 4 quarters · filed 2020-03-02 |
| 2019-03-31 | $2.38M 10-Q · filed 2019-05-02 | $6.14M derived: sum of 2 quarters · filed 2020-03-02 | $9.43M derived: sum of 3 quarters · filed 2020-03-02 | $12.00M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-12-31 | $3.76M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $7.05M derived: sum of 2 quarters · filed 2020-03-02 | $9.63M derived: sum of 3 quarters · filed 2020-03-02 | $12.67M 10-K · filed 2020-03-02 |
| 2018-09-30 | $3.29M 10-Q · filed 2019-10-30 | $5.86M derived: sum of 2 quarters · filed 2019-10-30 | $8.91M 10-Q · filed 2019-10-30 | $11.34M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $2.57M 10-Q · filed 2019-08-06 | $5.62M 10-Q · filed 2019-08-06 | $8.05M derived: sum of 3 quarters · filed 2020-03-02 | $9.63M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $3.04M 10-Q · filed 2019-05-02 | $5.48M derived: sum of 2 quarters · filed 2020-03-02 | $7.06M derived: sum of 3 quarters · filed 2020-03-02 | $7.82M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $2.44M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $4.02M derived: sum of 2 quarters · filed 2020-03-02 | $4.78M derived: sum of 3 quarters · filed 2020-03-02 | $4.58M 10-K · filed 2020-03-02 |
| 2017-09-30 | $1.58M 10-Q · filed 2018-11-05 | $2.34M derived: sum of 2 quarters · filed 2018-11-05 | $2.14M 10-Q · filed 2018-11-05 | |
| 2017-06-30 | $758.00K 10-Q · filed 2018-08-07 | $797.00K 10-Q · filed 2018-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |